Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder
Status:
Active, not recruiting
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
ABACUS is an open-label, international, multi-centre, window of opportunity phase II trial
for patients with histologically confirmed (T2-T4a) transitional cell carcinoma of the
bladder. The trial aims to test the efficacy of preoperative MPDL3280A and will include
extensive biomarker work on samples from these patients. Eligible patients will receive two
3-weekly cycles of MPDL3280A pre-cystectomy. Following cystectomy, patients will be followed
up for safety, survival, and disease data.